Bristol Myers Squibb Co $49.12

up +0.20


22/7/2014 04:00 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has underperformed the S&P 500 by 8%

Partner Headlines

  1. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  2. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  3. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  4. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  5. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  6. Bristol seeks cancer drug nod

    IBD
  7. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  8. Japan approves BMY regimen

    IBD
  9. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  10. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  11. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  12. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  13. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  14. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  15. Benzinga's Top Downgrades

    Benzinga
  16. Ex-Dividends For July 1, 2014

    Benzinga
  17. Pfizer and others get EU nods

    IBD
  18. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  19. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  20. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  21. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  22. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  23. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  24. BRISTOL-MYERS SQUIBB

    IBD
  25. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  26. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  27. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  28. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  29. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  30. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  31. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  32. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  33. Bristol, Merck Q1 sales soft

    IBD
  34. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  35. ETF Outlook For Tuesday, April 29, 2014 (IHE, TAN, XRT, SOCL, TWTR)

    Benzinga
  36. UPDATE: Bristol-Myers Posts Higher Q1 Profit

    Benzinga
  37. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  38. Bristol-Myers Squibb Acquires iPierian for $175M, Potential Milestone Payments ...

    Benzinga
  39. Earnings Scheduled For April 29, 2014

    Benzinga
  40. Stocks To Watch For April 29, 2014

    Benzinga
  41. Pfizer Confirms Pursuit Of AstraZeneca; Stocks Jump

    IBD
  42. Earnings Expectations For The Week Of April 28: Big Oil, Big Pharma And ...

    Benzinga
  43. Benzinga Weekly Preview: Earnings Season Continues As Biotech & Pharmaceutical ...

    Benzinga
  44. Week Ahead: April Jobs Report, FOMC Meeting and Earnings

    FoxBusiness
  45. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  46. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo ...

    Benzinga
  47. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  48. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  49. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  50. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
Trading Center